Q2 2024 Trinity Biotech PLC Earnings Call Transcript
Key Points
- Trinity Biotech PLC (TRIB) reported over 50% quarter-on-quarter revenue growth in point-of-care revenue, driven by the successful scaling of rapid HIV test output.
- The company achieved a 45% improvement in operating profitability before impairment charges and restructuring costs quarter over quarter.
- Trinity Biotech PLC (TRIB) is on track to achieve annualized run rate revenues of approximately $75 million by Q2 2025 with $20 million in EBITDASO.
- The company successfully implemented further automation of manufacturing processes, reducing the net cost of manufacturing.
- Trinity Biotech PLC (TRIB) has made significant progress in its comprehensive transformation plan, including offshoring manufacturing and optimizing the supply chain.
- Clinical laboratory revenues decreased by 4.6% compared to Q2 2023, primarily due to lower hemoglobins revenues.
- The company incurred restructuring costs totaling $1.9 million related to its comprehensive transformation plan.
- TrinScreen HIV sales are currently diluting the overall margin percentage, although improvements are expected in the future.
- Net loss from continuing operations was $6.8 million in the quarter, compared to $18.3 million in the same quarter last year.
- The cash balance decreased from $5.8 million at March 31 to $5.3 million at the end of June, with cash used by operations amounting to $1.1 million in the quarter.
Welcome to the Trinity Biotech second-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.
I will now turn the call over to Eric Ribner. Thank you. You may begin.
Thank you. And before we begin, please note that statements made during this presentation may be deemed forward-looking statements within the meaning of federal securities laws. These statements are subject to known and unknown risks and uncertainties and may cause actual events to differ from those expressed or implied in such statements. These risks include but are not limited to those set forth in the risk factor statements in the company's annual report on Form 20-F filed with the SEC. Trinity Biotech undertakes no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after today or the occurrence of unanticipated events.
I will now hand the call over to John Gillard, President and CEO of Trinity Biotech, who will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
